Price to sales forward of Janux Therapeutics, Inc. – NASDAQ:JANX
The article focuses on the "Price to sales forward" metric for Janux Therapeutics, Inc. (NASDAQ: JANX). It appears to be a financial data page from TradingView, providing an overview of the company's financial information, technical analysis, and market data. The content is primarily a listing of navigation and service offerings from the TradingView platform.
Price to earnings forward of Janux Therapeutics, Inc. – NASDAQ:JANX
This article provides financial information for Janux Therapeutics, Inc. (NASDAQ: JANX) focusing on its price to earnings forward metric. The content highlights a specific period, its value, and the percentage change. It appears to be an excerpt from a financial data platform like TradingView.
Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 2500 Growth Benchmark
Janux Therapeutics, Inc. (JANX) has been removed from the Russell 2500 Growth Benchmark, as well as the Russell 2000 Growth, Russell 3000E Growth, and Russell Small Cap Comp Growth benchmarks. This news follows a series of recent updates including leadership changes, analyst price target adjustments, Q1 2026 earnings results, and the discontinuation of a cancer drug candidate, JANX008. The company is a clinical-stage biopharmaceutical firm developing tumor-activated immunotherapies for cancer.
Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 3000 Growth Benchmark
Janux Therapeutics, Inc. (NasdaqGM: JANX) has been removed from the Russell 3000 Growth Benchmark, as well as the Russell 2500, Russell 2000, and Russell 3000E Growth Benchmarks. This news follows several other recent updates for the company, including leadership changes, adjusted price targets from analysts, and reports on its Q1 revenue and clinical trial developments.
Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 2000 Growth Benchmark
Janux Therapeutics, Inc. (NasdaqGM:JANX) has been removed from the Russell 2000 Growth Benchmark as of June 29, 2026. The biopharmaceutical company is currently developing tumor-activated immunotherapies for cancer, utilizing its TRACTr, TRACIr, and ARM bispecific platforms. This news follows several recent updates including earnings results, analyst rating adjustments, and the discontinuation of development for one of its cancer drug candidates.
5 Most Promising Cancer Stocks According to Wall Street Analysts
This article identifies five promising cancer stocks according to Wall Street analysts, focusing on companies with significant price target upsides and pipeline developments. It highlights Janux Therapeutics, Inc. (NASDAQ:JANX) as one such company, detailing analyst ratings, its TRACTr platform, and recent leadership changes while emphasizing that its development strategy remains unaffected. The full article, which lists 10 companies, is available on the Insider Monkey website.
Discipline and Rules-Based Execution in JANX Response
Stock Traders Daily's Quantitative Research Desk has analyzed Janux Therapeutics Inc. (NASDAQ: JANX), identifying strong near and mid-term sentiment but a weak long-term outlook. The analysis highlights an exceptional risk-reward short setup targeting a 29.6% downside with minimal risk. Three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—are provided for different risk profiles.
JANX Forecast — Price Target — Prediction for 2027
The article provides a forecast and price target for Janux Therapeutics, Inc. (JANX) stock for 2027, based on analyst ratings and estimates. It includes current stock performance data, financial metrics like revenue and earnings, and answers frequently asked questions about the company's stock, such as its historical performance, volatility, market capitalization, and upcoming earnings dates.
Janux Therapeutics, Inc. Actuals & Estimates (NASDAQ:JANX)
This article provides an overview of Janux Therapeutics, Inc. (NASDAQ: JANX) stock, including its current price, performance, and analyst forecasts. It details financial actuals and estimates, such as earnings per share and revenue for past quarters, and also provides upcoming earnings dates and other key financial metrics like market capitalization and EBITDA. The content further offers guidance on how to research and potentially invest in JANX stock.
Truist Financial Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $26
Truist Financial has initiated coverage on Janux Therapeutics (JANX.US) with a Buy rating. The firm has set a target price of $26 for the company's shares. This indicates a positive outlook from Truist Financial regarding Janux Therapeutics' future performance.
JANX Forecast — Price Target — Prediction for 2027
This article provides a forecast for Janux Therapeutics, Inc. (JANX) stock, including a 1-year price target of 27.20 CHF based on 16 analysts, with a max estimate of 48.62 CHF and a min estimate of 11.34 CHF. It also details recent financial performance, such as last quarter's earnings per share of -0.31 CHF with a 29.16% surprise, and projects future revenue and earnings.
Janux Therapeutics (NasdaqGM:JANX) Stock Forecast & Analyst Predictions
Janux Therapeutics (JANX) is forecast to experience a decline in earnings at 16.8% per annum, while revenue is expected to grow by 47.7% annually. The company, which is currently unprofitable, has seen various price target changes and estimate revisions from analysts. Recent updates include a decrease in a price target to US$40.56 and the departure of its Chief Medical Officer, alongside progress in its clinical programs for cancer and autoimmune diseases.
Form 8K Janux Therapeutics Inc For: 23 June By Investing.com
This article announces that Janux Therapeutics Inc. filed a Form 8K for June 23. This is a brief notice from Investing.com, highlighting the company's regulatory filing. The notice includes their stock symbol JANX and its recent performance.
CMO exits Janux Therapeutics (NASDAQ: JANX) as company starts search
Janux Therapeutics announced the departure of its Chief Medical Officer, William Go, M.D., Ph.D., on June 23, 2026. The company stated his departure was a termination without "Cause" and does not reflect any disagreement over operations or strategy. Janux will begin a search for a new CMO, with existing clinical leaders managing responsibilities in the interim, ensuring no change to development strategy, regulatory plans, or clinical timelines.
Janux Therapeutics Inc (JANX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey focuses on Janux Therapeutics Inc. (JANX)'s revenue breakdown, but states that the relevant data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. It provides current stock information for JANX, including its market capitalization, and lists various financial analysis tools available on the TradingKey platform.
Janux Therapeutics Inc (JANX) Dividends & Stock Splits: Historical Payouts and Event Timeline
The article provides an overview of Janux Therapeutics Inc. (JANX) regarding its dividends and stock splits. It states that the company has not distributed any dividends over the past five years and has no historical stock split data available. Financial data for JANX, including its market capitalization, is also presented.
Janux Therapeutics Inc (JANX) Institutional Confidence
Janux Therapeutics Inc (JANX) has an institutional shareholding score of 10.00, placing it first among 388 companies in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 110.21%, showing a 0.64% increase quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 1.11M shares, despite a 62.25% decrease in his holdings.
Janux Therapeutics Inc (JANX) Risk Assessment: Volatility, Financial Risk & Investment Risk
Janux Therapeutics Inc (JANX) has a risk assessment score of 2.93, ranking 175 out of 388 in the Biotechnology & Medical Research industry, with a beta of 2.54 indicating higher volatility than the S&P 500. The company's risk profile includes a 240-day maximum drawdown of +64.94% and volatility of +83.65%, alongside a highly negative skewness of -5.63 over 240 days. Its Sharpe Ratios and return-to-drawdown ratios suggest mixed risk-adjusted performance across different periods.
JANX SEC Filings - Janux Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Janux Therapeutics (JANX) SEC filings, including annual, quarterly, and material event reports, as well as insider trading forms. It highlights recent filings such as Janus Henderson's passive ownership report, Adage Capital's stake disclosure, and a quarterly earnings report, with AI-generated summaries and sentiment analysis. The article also offers company data like market cap, float, industry, and headquarters location.
Janux Therapeutics Reports Results of 2026 Annual Meeting
Janux Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 11, 2026, where shareholders elected two Class II directors, ratified Ernst & Young LLP as the independent accounting firm, and approved executive compensation. The company's stock, JANX, currently holds a "Buy" rating with a $22.00 price target from analysts, although TipRanks' AI Analyst, Spark, rates it as Neutral due to ongoing losses and significant cash burn. Janux Therapeutics is a biotechnology company focused on developing novel therapeutics.
Janux Therapeutics (JANX) director reports RSU and option awards tied to RA Capital
Janux Therapeutics director Jake Simson reported receiving 5,500 restricted stock units (RSUs) and options for 15,500 shares, with vesting tied to continuous service. These equity awards are held for the benefit of RA Capital Healthcare Fund and RA Capital Nexus Fund II, aligning with an arrangement where Simson disclaims beneficial ownership and any net proceeds offset advisory fees owed to RA Capital Management. This transaction was disclosed in a Form 4 SEC filing, detailing the vesting schedules and the ultimate beneficial owners of these awards.
Janux Therapeutics (JANX) director awarded RSUs and stock options
Janux Therapeutics director Natasha Hernday received 5,500 restricted stock units (RSUs) and stock options for 15,500 shares. The RSUs vest by June 11, 2027, or the next annual stockholder meeting, while the stock options vest monthly over 12 months from June 11, 2026, both subject to continued service. Following these transactions, Hernday directly holds 15,481 common shares.
Director of Janux Therapeutics (JANX) receives new RSU and stock option awards
Winston Kung, a director at Janux Therapeutics (JANX), has received new equity awards comprising 5,500 restricted stock units (RSUs) and 15,500 stock options with an exercise price of $13.66 per share. The RSUs are set to vest by June 11, 2027, or the next annual stockholder meeting, while the stock options will vest in equal monthly installments over 12 months starting June 11, 2026, both contingent on continuous service. Following these grants, Mr. Kung directly holds 11,750 shares of common stock in Janux Therapeutics.
Director at Janux Therapeutics (JANX) gets new RSUs and stock options
Janux Therapeutics director Vickie L. Capps was granted 5,500 restricted stock units (RSUs) and options for 15,500 shares of common stock at an exercise price of $13.66 per share. Following these awards, her direct holdings increased to 79,598 shares. The RSUs and stock options are subject to vesting schedules, contingent on her continuous service with the company.
Janux Therapeutics (JANX) awards director RSUs and 15,500 options
Janux Therapeutics director Eric Dobmeier was awarded 5,500 restricted stock units (RSUs) and options to purchase 15,500 shares of common stock. The RSUs will vest on the earlier of June 11, 2027, or the next annual stockholder meeting, while the options have an exercise price of $13.66 per share and vest in equal monthly installments over 12 months starting June 11, 2026. These equity awards are part of his compensation and are tied to his continued service to the company.
Janux Therapeutics (JANX) awards RSUs and stock options to director
Janux Therapeutics director Ronald W. Barrett was granted 5,500 restricted stock units (RSUs) and a stock option for 15,500 shares at an exercise price of $13.66. These equity awards, detailed in a Form 4 SEC filing, are compensation-related and contingent on his continuous service, with specific vesting schedules for both the RSUs and stock options. After these transactions, Barrett directly holds 11,750 common shares and the option for 15,500 shares.
Shareholders back Janux Therapeutics (NASDAQ: JANX) board and pay
Janux Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Shareholders re-elected Class II directors Natasha Hernday and Eric Dobmeier, ratified Ernst & Young LLP as the independent registered public accounting firm, and approved, on an advisory basis, the compensation of named executive officers. These decisions reflect shareholder support for the company's current governance and executive pay practices.
Janux Therapeutics, Inc. (JANX) reports Q1 loss, lags revenue estimates
Janux Therapeutics (JANX) reported a Q1 2026 loss of $0.62 per share, which is wider than the Zacks Consensus Estimate of a $0.57 loss. The company's revenue for the quarter was $2.03 million, falling short of the consensus estimate of $2.26 million. Despite missing revenue expectations, the reported revenue represents a significant year-over-year increase from $0.05 million in the prior-year quarter.
Janux Therapeutics (JANX) details RSU and stock option grants to RA Capital–linked entities
Janux Therapeutics (JANX) reported equity awards tied to RA Capital-associated entities, specifically grants of 5,500 restricted stock units (RSUs) and 15,500 stock options to Dr. Jake Simson with an exercise price of $13.66. These awards are linked to Dr. Simson's continuous service and vest over time, with any net value being remitted to RA Capital's adviser to offset advisory fees. The filing indicates these are routine compensation awards rather than open-market trades, with RA Capital and associated individuals disclaiming beneficial ownership beyond pecuniary interest.
B of A Securities Maintains Janux Therapeutics (JANX) Buy Recommendation
B of A Securities has reiterated its Buy recommendation for Janux Therapeutics (JANX). This indicates a continued positive outlook from the firm regarding the company's stock performance and future prospects.
B of A Securities Maintains Janux Therapeutics (JANX) Buy Recommendation
B of A Securities has reiterated its Buy recommendation for Janux Therapeutics (JANX). This continued endorsement from the financial institution suggests a positive outlook on the company's stock performance and future prospects. Investors may view this as a reinforcing signal for their investment decisions regarding JANX.
JANX Technical Analysis & Stock Price Forecast
Janux Therapeutics Inc (JANX) is currently exhibiting a "Strong Sell" technical sentiment based on an aggregation of 15 technical signals, with 4 indicating buy and 11 indicating sell. The stock is trading below its 60-day and 200-day moving averages, and key indicators like MACD also suggest a sell signal. Its Relative Strength Index (RSI) is neutral at 36.182, with support at $13.256 and resistance at $14.966.
Janux Therapeutics officer Janeen Doyle sells $56,943 in stock
Janux Therapeutics' Chief Corporate and Business Development Officer, Janeen Noel Doyle, sold 4,059 shares of company stock worth approximately $56,943 to cover tax withholding obligations. This transaction occurred as JANX stock is trading near its 52-week low, amidst news of the company discontinuing one clinical program while advancing another for prostate cancer. Analyst ratings for Janux Therapeutics are mixed, with one firm maintaining a "buy" rating and another downgrading to "underweight."
(JANX) Movement Within Algorithmic Entry Frameworks
The article provides an algorithmic analysis of Janux Therapeutics Inc. (NASDAQ: JANX), indicating a near-term weak sentiment that may lead to a resumption of long-term weakness. It highlights an exceptional 127.2:1 risk-reward setup targeting a 41.3% gain versus a 0.3% risk, with specific institutional trading strategies outlined for position trading, momentum breakout, and risk hedging. Multi-timeframe signal analysis also details support and resistance levels for various time horizons.
Janux Therapeutics officer Janeen Doyle sells $56,943 in stock
Janux Therapeutics officer Janeen Doyle sold 4,059 shares of the company's common stock for approximately $56,943 to cover tax withholding obligations. This transaction leaves Ms. Doyle with 75,941 shares, as JANX stock faces a recent decline and volatility. The company is discontinuing one clinical program but advancing others, receiving mixed analyst ratings.
Janux Therapeutics officer Janeen Doyle sells $56,943 in stock
Janux Therapeutics' Chief Corporate and Business Development Officer, Janeen Doyle, sold 4,059 shares of company stock worth $56,943 to cover tax obligations. This sale comes as JANX stock has seen a significant decline, trading nearly 61% below its 52-week high, amidst recent developments including the discontinuation of one clinical program and the initiation of another for prostate cancer. Analyst ratings for Janux Therapeutics are mixed, with some reiterating "buy" while others have downgraded the stock.
Janux Therapeutics (JANX) officer auto-sells 4,059 shares to cover RSU taxes
Janux Therapeutics' Chief Corp. & Business Development Officer, Janeen Noel Doyle, automatically sold 4,059 shares of common stock at a weighted average price of $14.029 per share on June 2, 2026. This transaction was non-discretionary and performed to cover tax withholding obligations associated with the vesting of restricted stock units. Following the sale, Doyle directly holds 75,941 shares of Janux Therapeutics common stock.
4,059 RSUs to be Sold by JANX (NASDAQ: JANX)
Janux Therapeutics (NASDAQ: JANX) has filed a Form 144 indicating a proposed sale of 4,059 shares of Common Stock. These shares are related to Restricted Stock Units (RSUs) that vested on June 1, 2026, under a registered plan, with the filing occurring on June 2, 2026. Morgan Stanley Smith Barney is identified as the broker for this transaction.
Janux Therapeutics, Inc. - Common Stock (NQ: JANX)
This article provides a compilation of recent news headlines, press releases, and research updates concerning Janux Therapeutics, Inc. (Nasdaq: JANX). The news dates range from July 2023 back to June 2022, covering clinical data announcements, executive appointments, financial results, investor conference participations, and analyst insights. It offers a chronological overview of key developments for the biotech company.
Here's Why You Should Add JANX Stock to Your Portfolio Now
Janux Therapeutics (JANX) is highlighted as a compelling investment opportunity due to significant progress in its oncology and immunotherapy pipeline, including lead candidate JANX007 for prostate cancer. The company has also expanded into autoimmune diseases and forged strategic collaborations with Merck & Co. and Bristol Myers Squibb. Janux Therapeutics currently holds a Zacks Rank #2 (Buy), with narrowed loss per share estimates for 2026 and 2027.
Wall Street analysts predict a 155.82% upside in Janux Therapeutics (JANX): Here's what you should know
The article discusses Janux Therapeutics (JANX) and the significant upside potential predicted by Wall Street analysts. It highlights that the stock has received a Strong Buy consensus rating, with an average price target indicating a 155.82% increase. The piece suggests that this strong analyst confidence stems from the company's recent performance and future prospects, urging investors to consider these projections.
JANX Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of Janux Therapeutics Inc (JANX), detailing its revenue breakdown, profitability margins, and a comparison with competitors MGTX and SANA. Key metrics include a 100% gross margin, -916.50% operating margin, and -652.59% net margin, alongside a negative Return on Equity. The article highlights JANX's market capitalization of $885.49M and positions it against industry leaders, emphasizing its strong gross margin relative to competitors.
How (JANX) Movements Inform Risk Allocation Models
This article analyzes Janux Therapeutics Inc. (NASDAQ: JANX) using AI models, indicating a stable neutral reading in shorter horizons with a mid-channel oscillation pattern. It presents three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles, and highlights an exceptional 130.7:1 risk-reward setup targeting a 40.8% gain. The analysis includes multi-timeframe signal data, with a weak long-term signal.
Janux Therapeutics (JANX) price target decreased by 14.60% to 42.12
This article reports a significant 14.60% decrease in the price target for Janux Therapeutics (JANX), bringing it down to $42.12. The specific reasons or analyst behind this adjustment are not detailed in the provided content.
Janux Therapeutics (JANX) price target decreased by 14.60% to 42.12
This article reports a significant decrease in the price target for Janux Therapeutics (JANX) by 14.60%, bringing it down to $42.12. This adjustment suggests a revised outlook from analysts regarding the company's future stock performance and valuation. The specific reasons for this reduction were not detailed in the provided content.
Insider Sell: Maria Dobek Sells Shares of Janux Therapeutics Inc (JANX)
Maria Dobek, Vice President of Accounting at Janux Therapeutics Inc (JANX), sold 2,038 shares of the company on May 11, 2026, and now holds 32,270 shares. This transaction is part of a pattern of 10 insider sells and no buys over the past year. The stock is currently trading at $14.17, with a GF Value of $34.56, suggesting it might be a "Possible Value Trap, Think Twice."
Janux Therapeutics (JANX) VP sells 2,038 shares at $14.17
Maria Dobek, Vice President of Accounting at Janux Therapeutics (JANX), sold 2,038 shares of company common stock in an open-market transaction on May 11, 2026, at a price of $14.17 per share. This sale reduced her direct holdings to 32,270 shares. The transaction, valued at approximately $29,000, was reported in an SEC Form 4 filing.
Bullish: Analysts Just Made A Meaningful Upgrade To Their Janux Therapeutics, Inc. (NASDAQ:JANX) Forecasts
Analysts have significantly upgraded their forecasts for Janux Therapeutics, Inc. (NASDAQ:JANX), increasing revenue estimates for 2026 to US$34 million and reducing projected losses per share to US$1.77. This suggests a notable improvement in business fundamentals and an expectation of accelerated growth. Despite the positive outlook on revenues and reduced losses, the consensus price target coincidentally fell by 8.1% to US$40.56, indicating some continued pessimism among analysts.
How much upside is left in Janux Therapeutics (JANX)? Wall Street analysts think 180.44%
This article discusses the potential upside for Janux Therapeutics (JANX) as perceived by Wall Street analysts, who estimate a significant increase of 180.44%. It suggests that the stock could see substantial growth based on current analyst projections.
Janux Therapeutics halts early stage cancer program in 'prudent' move
Janux Therapeutics has announced the discontinuation of its early-stage cancer drug program, JANX008, affecting non-small cell lung cancer patients. The decision was made following an internal strategic review, which determined that while the drug showed anti-tumor activity and was well-tolerated, its potential for differentiation in the competitive treatment landscape was insufficient. The company will now reallocate resources to its other clinical programs, including JANX007 and JANX003, which target different cancer types.
